Lung Cancer
HEROEX-1 Trial Begins for HER2-Selective Inhibitor NVL-330 in NSCLC
The first pretreated patient with HER2-altered non–small cell lung cancer was dosed with NVL-330, a novel HER2-selective inhibitor, in the HEROEX-1 trial.
Read More
FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC
In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
Listen
Amivantamab/Lazertinib Leads to Longer PFS, Duration of Response in EGFR+ NSCLC
Findings from the MARIPOSA trial showed that amivantamab plus lazertinib were superior to osimertinib for the treatment of EGFR-mutant non–small cell lung cancer.
Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care
In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.
Landmark Studies Propel Lung Cancer Treatment Forward
In an interview, Aakash Desai, MD, MPH, discussed significant lung cancer treatment advancements that were highlighted at ASCO 2024.
COVID's Shadow on Lung Cancer? Study Sees Later Diagnoses
Jessica Paulus, ScD, discussed a study investigating real-world trends in lung cancer staging among community oncology practices.
